Brief Intervention in Primary Care for Problem Drug Use and Abuse
This study is ongoing, but not recruiting participants.
Sponsor:
University of Washington
Collaborator:
Information provided by (Responsible Party):
University of Washington
ClinicalTrials.gov Identifier:
NCT00877331
First received: April 6, 2009
Last updated: November 6, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will examine the effectiveness of a brief intervention in a primary care setting to reduce drug use or abuse compared to enhanced care as usual.
| Condition | Intervention |
|---|---|
|
Substance-Related Disorders |
Behavioral: Brief Intervention using motivational interviewing |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Brief Intervention in Primary Care for Problem Drug Use and Abuse |
Further study details as provided by University of Washington:
Primary Outcome Measures:
- Effectiveness of the intervention to reduce use of illicit drugs will be measured by self-reported days of use in the past 30 days and validated by urine toxicological screen. [ Time Frame: baseline, 3, 6, 9, and 12 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Effectiveness of the intervention to increase attendance in drug abuse treatment programs will be measured by self-report and by administrative data review. [ Time Frame: baseline, 3, 6, 9, and 12 months ] [ Designated as safety issue: No ]
- Effectiveness of the intervention to reduce use of illicit drugs in individuals with milder hazardous use will be measured by self-reported scores on assessments. [ Time Frame: baseline, 3, 6, 9, and 12 months ] [ Designated as safety issue: No ]
- Testing whether intervention fidelity is associated with better outcomes will be measured by scoring interventionists' proficiency. [ Time Frame: one-time intervention at baseline ] [ Designated as safety issue: No ]
- Effectiveness of the intervention to impact public health outcomes will be measured by administrative data sources (emergency room visits, hospitalizations, hospital days, HIV risk behavior, arrests, and death). [ Time Frame: baseline through 2 years post-intervention ] [ Designated as safety issue: No ]
- Effectiveness of the study to estimate costs of the intervention compared to the control arm will be measured by administrative data. [ Time Frame: baseline through 2 years post-intervention ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 1000 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | September 2014 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Brief intervention using motivational interviewing. One in-person session (30-45 minutes) with a brief phone follow-up one week later.
|
Behavioral: Brief Intervention using motivational interviewing
One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
|
|
No Intervention: 2
Enhanced care as usual.
|
Detailed Description:
A substantial body of research has established the efficacy and effectiveness of brief interventions (BI) for excessive or "hazardous" alcohol use in patients seen in medical settings. Dissemination projects of brief interventions for alcohol and drugs have recently been implemented on a widespread scale. This rapid progression of brief intervention for drugs other than alcohol has outstripped its evidence base.
The aims of the study are:
- To examine whether BI is effective at improving outcomes in individuals with a wide range of problem drug use over and above enhanced care as usual. The enhanced control condition will consist of routine screening, patient notification, and referral for treatment.
- To test whether fidelity to the BI model is associated with better outcomes.
- To estimate the impact of BI on several public health outcomes that are directly related to the hazardous effects of illicit drug use, including the use of acute health care services, involvement in the criminal justice system, employment, HIV risk behavior, and mortality.
- To estimate the costs of the intervention, potential cost offsets, and its incremental cost-effectiveness versus enhanced usual care from the payer perspective based on health care service use and drug use frequency.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- at least 18 years old
- receive medical care at one of the four participating primary care clinics at Harborview Medical Center (Adult Medicine Clinic, Family Medicine Clinic, Women's Clinic, and Pioneer Square Clinic)
- will maintain care at Harborview Medical Center for one year
- have a phone or easy access to phone, voicemail, or email
- used recreational drugs in the last 3 months
- used prescription medications not as prescribed in the last 3 months
Exclusion Criteria:
- participation in any formal substance abuse treatment programs in the last 30 days (excluding 12-step or self-help groups)
- terminal illness
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00877331
Locations
| United States, Washington | |
| Harborview Medical Center | |
| Seattle, Washington, United States, 98104 | |
Sponsors and Collaborators
University of Washington
Investigators
| Principal Investigator: | Peter P Roy-Byrne, MD | University of Washington |
| Study Director: | Dennis M Donovan, PhD | University of Washington |
| Study Director: | Christopher W Dunn, PhD | University of Washington |
| Study Director: | Jutta M Joesch, PhD | University of Washington |
| Study Director: | Antoinette Krupski, PhD | University of Washington |
| Study Director: | Richard K Ries, MD | University of Washington |
| Study Director: | Jeanne Sears, PhD | University of Washington |
| Study Director: | Sharon Estee, PhD | WA Dept of Social & Health Services |
| Study Director: | Gary Zarkin, PhD | RTI International |
More Information
No publications provided by University of Washington
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | University of Washington |
| ClinicalTrials.gov Identifier: | NCT00877331 History of Changes |
| Other Study ID Numbers: | DESPR DA026014, R01DA026014 |
| Study First Received: | April 6, 2009 |
| Last Updated: | November 6, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by University of Washington:
|
Drug Abuse Drug Addiction Drug Dependence Drug Usage Drug Use Disorders |
Substance Abuse Substance Addiction Substance Dependence Substance Use Disorders |
Additional relevant MeSH terms:
|
Substance-Related Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 21, 2013